Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1”

1,582 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,582 results

Testing effectiveness (Phase 2)Study completedNCT03665285
What this trial is testing

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more
NextCure, Inc. 109
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07360743
What this trial is testing

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Who this might be right for
Non Small Cell Lung Cancer (Squamous or Non Squamous)
UNICANCER 275
Testing effectiveness (Phase 2)Study completedNCT05661578
What this trial is testing

Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Who this might be right for
PD-L1-selected Solid Tumors
Hoffmann-La Roche 64
Post-approval studies (Phase 4)Study completedNCT04489888
What this trial is testing

Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Merck Sharp & Dohme LLC 101
Early research (Phase 1)Study completedNCT03744403
What this trial is testing

CS1001 in Subjects with Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
CStone Pharmaceuticals 24
Not applicableUnknownNCT03078959
What this trial is testing

Prognostic Value of PD-L1 in NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 350
Large-scale testing (Phase 3)Looking for participantsNCT06170489
What this trial is testing

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Who this might be right for
Hodgkin Lymphoma
Shanghai Junshi Bioscience Co., Ltd. 185
Early research (Phase 1)Ended earlyNCT03936959
What this trial is testing

LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 10
Early research (Phase 1)Looking for participantsNCT07538479
What this trial is testing

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

Who this might be right for
Solid TumorsSolid MalignanciesCold Exposure+1 more
West China Hospital 24
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Early research (Phase 1)WithdrawnNCT03196401
What this trial is testing

Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Who this might be right for
Solitary Bone Plasmacytoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06579196
What this trial is testing

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Who this might be right for
Non-small Cell Lung Cancer
University of Nebraska 45
Large-scale testing (Phase 3)Looking for participantsNCT06629597
What this trial is testing

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd. 400
Large-scale testing (Phase 3)Ended earlyNCT04866017
What this trial is testing

Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
BeiGene 63
Not applicableUnknownNCT05008796
What this trial is testing

PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT

Who this might be right for
Head and Neck Squamous Cell CarcinomaCirculating Tumor Cell
Chang Gung Memorial Hospital 50
Early research (Phase 1)Study completedNCT02350673
What this trial is testing

Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

Who this might be right for
Solid Tumors
Hoffmann-La Roche 70
Not applicableUnknownNCT05288569
What this trial is testing

IrAE Prediction of Anti-PD-1/L1 in Lung Cancer

Who this might be right for
Immune Checkpoint InhibitorsLung Cancer
Peking Union Medical College Hospital 120
Early research (Phase 1)Ended earlyNCT03665129
What this trial is testing

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Innate Pharma 73
Large-scale testing (Phase 3)Looking for participantsNCT06857175
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Who this might be right for
Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 508
Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Load More Results